Experimental Vaccine Seems to Stop Nicotine Addiction in Mice

background:url(http://l.yimg.com/a/p/us/news/editorial/a/5b/a5ba32682eb601fb573b57542c19b9c1.png);width:115px;height:25px;margin-left:50px;margin-top:7px

View the Original article

Weight Loss May Increase Testosterone Levels

HealthDay – 31 mins ago WEDNESDAY, June 27 (HealthDay News) -- Shedding pounds may help overweight men with low testosterone boost their levels of the male hormone, new research finds.

Overweight men are more likely to have low levels of testosterone, according to the study, which involved nearly 900 overweight, middle-aged Irish men with pre-diabetes. People with pre-diabetes have abnormally high blood glucose levels, but the levels aren't yet high enough to be considered diabetes.

Men were assigned to one of three treatments. One group was told to eat a lower-fat, lower-calorie diet and exercise at least 150 minutes a week; a second group took the diabetes drug metformin; and a third group took a placebo pill.

Among men in the healthy-lifestyle group, the rate of low testosterone levels dropped from 20 percent to 11 percent after a year. The rate of low testosterone didn't budge in the diabetes-drug group or the placebo group.

The study was expected to be presented this week at the Endocrine Society's annual meeting in Houston.

"Doctors should first encourage overweight men with low testosterone levels to try to lose weight through diet and exercise before resorting to testosterone therapy to raise their hormone levels," study co-author Dr. Frances Hayes, a professor at St. Vincent's University Hospital in Dublin, said in a society news release.

The healthy lifestyle group lost an average of 17 pounds.

"Losing weight not only reduces the risk of pre-diabetic men progressing to diabetes, but also appears to increase their body's production of testosterone," Hayes said.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal. Experts also note that the study found an association between weight loss and higher testosterone, but did not prove that losing weight caused testosterone levels to rise.

More information

The American Diabetes Association provides more information on prediabetes.

View the Original article

Pictures of Fatty, Sugary Foods May Spur Cravings

HealthDay – 31 mins ago WEDNESDAY, June 27 (HealthDay News) -- Looking at pictures of hamburgers, cupcakes and other high-calorie edibles can trigger cravings for fattening foods, especially if you're drinking something sweet at the time, according to a new study.

Researchers from the University of Southern California found that drinking a sugary beverage while viewing these foods activates appetite and reward centers in the brain, which could play a role in obesity.

"Studies have shown that advertisements featuring food make us think of eating, but our research looked at how the brain responds to food cues and how that increases hunger and desire for certain foods," said the study's principal investigator, Kathleen Page, assistant professor of clinical medicine at the university's Keck School of Medicine, in a university news release.

"This stimulation of the brain's reward areas may contribute to overeating and obesity, and has important public health implications," said Page.

In conducting the study, the researchers measured the brain responses of 13 obese, Hispanic females, aged 15 to 25 years, as they looked at both high-calorie and low-calorie foods.

Using functional magnetic resonance imaging (fMRI), the women's brains were scanned twice as they viewed images of foods such as hamburgers, cookies, cakes, fruits and vegetables.

After seeing all of the images, they were asked to rate their hunger as well as their desire for sweet or savory foods.

Halfway through the scans, the women drank 50 grams of glucose, which is similar to drinking a can of sugary soda. In a separate instance, they drank 50 grams of fructose. Glucose and fructose are found in table sugar and high-fructose corn syrup.

"We hypothesized that the reward areas in the women's brains would be activated when they were looking at high-calorie foods, and that did happen," said Page. "What we didn't expect was that consuming the glucose and fructose would increase their hunger and desire for savory foods."

The researchers pointed out that fructose resulted in more intense cravings and hunger among the women than glucose.

"Our bodies are made to eat food and store energy, and in prehistoric days, it behooved us to eat a lot of high-calorie foods because we didn't know when the next meal was coming," Page said.

"But now we have much more access to food, and this research indicates added sweeteners might be affecting our desire for it," she added in the news release.

The researchers said they limited the study to Hispanic women because research has indicated women are more sensitive to food cues, and the Hispanic community has a high incidence of obesity and type 2 diabetes.

More studies are needed to explore whether these cravings are due to obesity or genetics, the authors noted.

The study was presented Tuesday at the Endocrine Society's annual meeting in Houston. Data and conclusions of research presented at meetings should be considered preliminary until published in a peer-reviewed medical journal.

More information

The U.S. National Library of Medicine provides tips on how to tame food cravings.

View the Original article

Health Highlights: June 27, 2012

HealthDay – 31 mins ago Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

CDC Launches Free Drugstore HIV Testing

Drugstore testing for HIV may someday become routine if a government-sponsored pilot program catches on across the United States.

Free rapid HIV tests -- like those used in doctor's office and health clinics -- are available now at seven sites around the country, and the U.S. Centers for Disease Control and Prevention (CDC) announced Tuesday that it plans to add 17 more pharmacies and in-store clinics in cities and rural regions, the Associated Press reported.

"By bringing HIV testing into pharmacies, we believe we can reach more people by making testing more accessible and reduce the stigma associated with HIV," Dr. Kevin Fenton, director of CDC's HIV prevention program, said in a statement.

The HIV saliva test, which involves swabbing the mouth, provides preliminary results in 20 minutes. Customers with positive results will be referred for laboratory testing and, if the results are confirmed, counseling and treatment, the AP said.

While gay men and injectable drug users are considered at highest risk, the CDC currently recommends all teenagers and adults up to age 64 get tested at least once. The agency estimates that one-fifth of the 1.1 million Americans infected with HIV don't know they carry the virus that causes AIDS.

CDC, which is training drugstore personnel to administer the tests, will review the program results next summer.

-----

Bagged Salads Recalled From Kroger, Wal Mart Stores

The Dole company is recalling fresh bagged salads from Kroger and Wal Mart stores across six states due to potential contamination with listeria, the company has announced.

No illnesses have yet been reported in the "precautionary" recall of 1,077 cases of bagged salads that were distributed in Georgia, Kentucky, North Carolina, South Carolina, Tennessee and Virginia.

The products under recall include Kroger Fresh Selections Greener Supreme coded N158 211B 1613 KR04 with Use-by date of June 19 and UPC 11110 91039; Kroger Fresh Selections Leafy Romaine coded N158 111B KR11 with Use-by date of June 19 and UPC 11110 91046; and Wal Mart Marketside Leafy Romaine coded N158111B with Use-by date of June19 and UPC code 81131 02781.

The Product Code and Use-by dates are located in the upper right-hand corner of the salads' packaging, and the UPC is found on the reverse side of the package.

Dole is asking that consumers who have these products discard them. Retailers and consumers can find out more by calling Dole at 1-800-356-3111.

Listeria monocytigenes can trigger illness with symptoms such as fever, muscle ache and gastrointestinal symptoms, with pregnant women and people with compromised immune systems most at risk for serious illness.

-----

Low Testosterone Not Part of Normal Aging: Study

Factors other than aging are likely responsible for the drop in testosterone some older men experience, a new study finds.

Researchers in Australia tracked the testosterone levels of more than 1,500 men, ages 35 to 80, who had their testosterone levels sampled at clinic visits spaced five years apart, UPI reported.

The study found that testosterone levels didn't undergo a steep decline -- instead they only fell less than 1 percent per year. And certain health or lifestyle factors seemed linked to those slight declines.

"Men who had declines in testosterone were more likely to be those who became obese, had stopped smoking or were depressed at either clinic visit," lead author Dr. Gary Wittert, professor of medicine at the University of Adelaide in Adelaide, said in a statement. "While stopping smoking may be a cause of a slight decrease in testosterone, the benefit of quitting smoking is huge."

Wittert and his team believe, therefore, that a drop in testosterone is not an inevitable part of the aging process in men.

The study was presented at the Endocrine Society's 94th annual meeting in Houston.

-----

View the Original article

FDA Probing Safety of Metal-on-Metal Hip Implants

HealthDay – 31 mins ago TUESDAY, June 26 (HealthDay News) -- While thousands of Americans have benefited from hip replacements over the years, problems with metal-on-metal implants can lead to troubles requiring surgery to replace defective devices, experts say.

Specifically, experts say, tiny fragments of metal can shear off from these joints, causing chronic pain or infection and raising levels of metals in the bloodstream. Experts estimate that more than 500,000 Americans have received a metal-on-metal hip joint, mostly between 2003 and 2010.

Worry over the failure rate of the implants, and the speed at which they were initially approved for the U.S. market, has led to a special two-day session, beginning Wednesday, by experts at the U.S. Food and Drug Administration.

"Data from recent studies and from FDA's own review show some patients experiencing complications, including the need for additional surgeries, which could be attributed to metal-on-metal hip implant devices," said FDA spokeswoman Michelle Bolek.

Since 1999, almost 17,000 problems with these devices have been reported to the FDA. Of these, more than 12,000 were reported last year alone.

According to the agency, the problems with metal-on-metal implants are about the same as those seen with polyethylene and ceramic implants, except for the specific risks caused by the metal itself.

But others say that when it comes to complications, metal-on-metal implants are in a class of their own. Writing earlier this month in the New England Journal of Medicine, Dr. Joshua Rising of the Pew Charitable Trusts, and colleagues said that "there is now compelling evidence that these implants fail at a higher rate than hip prostheses made of other materials; indeed, one type of metal-on-metal hip has a failure rate of nearly 50 percent at 6 years."

Responding to these concerns, the FDA panel is considering the risks and benefits of metal-on-metal implants and what might be needed to monitor the health of patients who have them.

Of the estimated 400,000 hip replacements done in the United States each year, 27 percent involve metal-on-metal devices, according to the FDA.

Critics, including an independent panel of experts at the Institute of Medicine, have noted that metal-on-metal implants may have been approved too quickly under the FDA's "fast-track" program for medical devices.

Responding to concerns, in May 2011 the FDA ordered manufacturers to carry out "post-market" studies, tracking the safety of metal-on-metal hip implants in recipients. But in the NEJM article, Rising and colleagues noted that most of these studies have yet to begin and their first results will take years to arrive.

The FDA's Bolek made it clear that the advisory panel meeting is not a regulatory meeting and is not intended to look at the process that brought the devices to the market, or to deal with any planned or current post-marketing studies.

Metal-on-metal devices have already been recalled twice. In 2008, a device from manufacturer Zimmer, the Durom Acetabular Component, was recalled because instructions were not clear.

And in 2010 a device from DePuy Orthopaedics Inc. was recalled because more patients than expected had to have new surgeries, according to the FDA.

Earlier this month, a device called the R3 Acetabular System from Smith & Nephew was taken off the market because the company said it was "not satisfied with the clinical results of this component."

In Europe these concerns have led to calls to ban metal-on-metal hip replacement devices. Writing in March in the journal The Lancet, British researchers concluded that "metal-on-metal stemmed articulations give poor implant survival compared with other options and should not be implanted." Metal-on-metal implants had a five-year failure rate of more than 6 percent, three times higher that seen with ceramic or plastic joints.

Banning metal-on-metal joints isn't an option being considered by the FDA panel at this time.

"During the panel meeting, FDA will discuss failure rates and modes for these devices, as well as any local and systemic complications that could result from metal debris and metal ion levels in the bloodstream from the device," Bolek said.

The panel will also discuss metal ion testing and soft tissue imaging, tools that can potentially be used in the clinical management of patients who have these devices, Bolek said.

"We will also review specific risk factors for specific patient populations and considerations for post-implant follow-up," she added.

Mindy Tinsley is a spokeswoman for metal implant maker DePuy Orthopaedics Inc., which is owned by Johnson & Johnson. She said that "DePuy believes that no single bearing surface meets the needs of all patients, and metal-on-metal implants provide the potential benefit of greater function and a lower risk of dislocation for some patients."

Tinsley also said that all metal-on-metal implants are not alike and they should not be grouped together if problems arise.

One orthopedic expert agreed. Dr. Joshua Jacobs, first vice president of the American Academy of Orthopaedic Surgeons, said that "metal-on-metal devices are not all the same. You have to go down to the individual product to fully understand the result. When you lump metal-on-metal together you miss a lot of important differences."

According to Jacobs, who is chairman of the department of orthopaedic surgery at Rush University Medical Center in Chicago, the advantages of metal-on-metal implants are that there is typically less wear on the joint, leading to less loosening and less bone loss over time.

In addition, he said, metal allows for a thinner, larger socket and head, which makes it less likely the hip will dislocate after surgery, which is a common failure of other types of hip replacement.

Still, given the problems with these devices, Jacobs agrees that patients need to be monitored.

"We are trying to learn the optimal way of monitoring patients with metal-on-metal implants, so we can understand when it is appropriate to intervene," he said. "Right now we are amassing clinical data to understand that better."

More information

For more on hip replacement, visit the American Academy of Orthopaedic Surgeons.

View the Original article

'Atkins'-Type Diets May Raise Risk of Heart Problems: Study

'modId':'mediasocialchromefriends','isPreLoad':0,'enableMediaTabEvent':0,'pageSize':12,'numFriends':null,'notificationCount':0,'property':'News','learnMorePath':'/activity-learn-more/','friendbarNotification':'0','friendbarRollup':'0','moduleConf':YAHOO.Media.Facebook.ModuleConf,'friendIdList':

View the Original article

Partial Frown Kept TV Reporter Off the Air

View the Original article

CDC trying out free AIDS tests at drugstores

"background-image:url('http://l2.yimg.com/bt/api/res/1.2/pjn2S5taem8qCK.IoO2pBg--/YXBwaWQ9eW5ld3M7Y2g9MTQ1OTtjcj0xO2N3PTIwOTY7ZHg9MDtkeT0wO2ZpPXVsY3JvcDtoPTEzMztxPTg1O3c9MTkw/http://media.zenfs.com/en_us/News/ap_webfeeds/8f7f1835ea61a611130f6a706700d414.jpg');" width

View the Original article

Athletes' deaths in workouts prompt new guidelines

"http://l3.yimg.com/bt/api/res/1.2/GO7Rf1qdF2culyxJYYalsw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTcwO3B4b2ZmPTUwO3B5b2ZmPTA7cT04NTt3PTcw/http://media.zenfs.com/en_us/News/ap_webfeeds/09c22a38048ec012130f6a7067006fbe.jpg" width

View the Original article

FDA approves first new weight-loss pill in decade

The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

Despite only achieving modest weight loss in clinical studies, the drug appeared safe enough to win the FDA's endorsement, amid calls from doctors for new weight-loss treatments.

The agency cleared the pill Wednesday for adults who are obese or are overweight with at least one medical complication, such as diabetes or high cholesterol.

The FDA denied approval for Arena's drug in 2010 after scientists raised concerns about tumors that developed in animals studied with the drug. The company resubmitted the drug with additional data earlier this year, and the FDA said there was little risk of tumors in humans.

With U.S. obesity rates nearing 35 percent of the adult population, many doctors have called on the FDA to approve new weight loss treatments.

But a long line of prescription weight loss offerings have been associated with safety problems, most notably the fen-phen combination, which was linked to heart valve damage in 1997. The cocktail of phentermine and fenfluramine was a popular weight loss combination prescribed by doctors, though it was never approved by FDA.

In a rare move, the FDA explicitly stated in a press release that Belviq "does not appear to activate" a chemical pathway that was linked to the heart problems seen with fen-phen.

The FDA says the drug acts on a different chemical pathway in the brain, which is believed to reduce appetite by boosting feelings of satiety and fullness.

Belviq is one of three experimental weight-loss drugs whose developers have been trying for a second time to win approval, after the FDA shot them all down in 2010 or early 2011 because of serious potential side effects.

Vivus Inc.'s Qnexa is thought to be the most promising of the drugs, achieving the most weight loss. But the FDA has delayed a decision on that pill until July.

Shares of San Diego-based Arena Pharmaceuticals Inc. jumped $3.03, or 34 percent, to $11.88 in trading Wednesday afternoon.

Arena's studies showed that patients taking Belviq, known generically as lorcaserin, had modest weight loss. On average patients lost just 3 to 3.7 percent of their starting body weight over a year. About 47 percent of patients without diabetes lost at least 5 percent of their weight or more, which was enough to meet FDA standards for effectiveness. By comparison, average weight loss with Qnexa is 11 percent, with more than 83 percent of patients losing 5 percent of their weight or more.

Side effects with the drug include depression, migraine and memory lapses.

In May a panel of expert advisers to the FDA voted 18-4 to recommend approval of Arena's drug, concluding that its benefits "outweigh the potential risks when used long term" in overweight and obese people.

Experts say the challenge of weight loss drug development lies in safely turning off one of the body's fundamental directives: to eat enough food to maintain its current weight.

While several drugs are available for short-term weight loss, until Wednesday there was only one FDA-approved prescription drug for long-term weight loss: Xenical from Roche, which is seldom prescribed because unpleasant digestive side effects and modest weight loss.

Other safety failures for diet pills have continued to pile up in recent years.

Four years ago Sanofi-Aventis SA discontinued studies of its highly anticipated pill Acomplia due to psychiatric side effects, including depression and suicidal thoughts. In 2010, Abbott Laboratories withdrew its drug Meridia after a study showed it increased heart attack and stroke.

View the Original article

Toxic legacy in Malaysia rare-earths village

"S. Panchavarnam, sitting with her grand children, tells her story during an interview in Malaysia's northern Perak state. She vividly remembers the choking smell she endured working at a timber mill adjacent to the Japanese rare-earth plant in 1987. Pregnant at the time, she frequently fell ill" title

View the Original article

German court rules religious circumcision on boys an assault

"background-image:url('http://l.yimg.com/bt/api/res/1.2/wGAaLkrKo_g.ginw2xV3gw--/YXBwaWQ9eW5ld3M7Y2g9Mzc0O2NyPTE7Y3c9NTEyO2R4PTA7ZHk9MDtmaT11bGNyb3A7aD0xMzk7cT04NTt3PTE5MA--/http://media.zenfs.com/en_us/News/afp.com/photo_1340731497258-2-0.jpg');" width

View the Original article